GBA1 and Parkinson disease: Currently there are 4 on-going clinical trials with high-dose Ambroxol at different doses with different study designs (out of 14 active Phase 1–3 trials evaluating drug therapies for GBA1-PD registered on ClinicalTrials.gov, as of 31 January 2024), yet none of them is an FDA-guided trial which will open the door for the commercialization of Ambroxol for the two indications mentioned above [20].